Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its price target, reflecting a meteoric rise in the company’s stock price in 2020. The stock closed at $17.81 on March 2. Analyst...
The FDA granted fast track designation to Kura Oncology’s (NASDAQ:KURA) tipifarnib for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma and nodal...
BTIG launched coverage of Avita Medical (NASDAQ:RCEL) with a “buy” rating and $10 price target. The stock closed at $8.32 on March 2. Avita’s RECELL system produces a suspension of spray-on-skin cells using a small...
Peer-reviewed, Nature Gene Therapy, published Ocugen’s (NASDAQ:OCGN) preclinical data of nuclear hormone receptor gene, NR2E3, as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases...
Echelon Wealth Partners upgraded Extendicare (TSX:EXE) to “buy” from “hold” but kept its price target at $9 after the company reported fourth quarter results. The stock closed at $7.85 (Canadian) on March 2. Analyst...
Karyopharm Therapeutics (NASDAQ:KPTI) reported positive topline results from its Phase 3 BOSTON study in patients with multiple myeloma who have received one-to-three prior lines of therapy. The study evaluated once...
Mackie Research downgraded Medexus Pharmaceuticals (TSXV:MDP; OTCQB:PDDPF) to “speculative buy” from “buy” and lowered its price target to $8.70 (Canadian) from $10.50 after the company acquired Ixinity, a recombinant...
BTIG lowered its price target for IMV (NASDAQ, TSX:IMV) to $5 from $8, citing uncertainty about data from the company’s ongoing Phase 2 study of DPX-Survivac in patients with advanced recurrent ovarian cancer. The stock...
Ra Medical Systems (NASDAQ:RMED) enrolled the first patient in its pivotal study of the DABRA excimer laser system for the treatment of peripheral vascular stenoses. DABRA is an atherectomy device that uses...
Dawson James Securities downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “neutral” from “buy” and suspended its price target, citing a recent financing that “took us by surprise.” The stock closed at 57 cents on Feb...